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superseded the use of SSKI. Some of the side-effects—such as
bitter metallic taste, nausea, rash and anorexia—have been the
reason for limited use, but it remains an inexpensive therapy in
developing countries. We elected to treat our patient, who was
first seen in a free clinic, with SSKI, an effective and inexpensive
drug, rather than using the newer, costly azole antifungal drugs.
There has been dramatic improvement in the lesions as shown
in Figure 2. The drawback of the drug is the adverse effect that
occurred in this patient several weeks after he started treatment.
We emphasize that in this era of cost containment, the use
of SSKI is an inexpensive and effective treatment for cutaneous/
lymphocutaneous sporotrichosis.
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Successful treatment of Actinobacillus actinomycetemcomitans
endocarditis with ofloxacin
Clin Microbiol Infect 2000: 6: 55–56
Endocarditis due to HACEK organisms (Haemophilus sp., Acti-
nobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella
corrodens, Kingella kingae) are usually treated with ampicillin or
ceftriaxone plus an aminoglycoside for 4 weeks. That treatment
can be difficult to achieve in patients with poor venous access
or in cases of allergy to b-lactam antibiotics. Fluoroquinolones
are antibiotics characterized by an excellent oral bioavailability
and a high diffusion in tissue and cardiac vegetations [1]. Thus,
they could be an interesting alternative to the b-lactam-ami-
noglycoside treatment. To our knowledge, only one case of
A. actinomycetemcommitans (Aa) endocarditis being successfully
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treated by fluoroquinolone has yet been reported [2]. We pre-
sent here a second case.
A 65-year-old man was admitted to the Infectious Disease
Department on January 1998. He had been suffering for 30 years
with mitral regurgitation complicating a mitral valve prolapse.
During the past 3 months, he presented with three febrile
episodes, each of which was rapidly resolved after an oral anti-
biotic treatment given by his family doctor. Successive echo-
cardiographic examinations performed by his cardiologist,
including a transoesophageal echocardiography, showed a
recent worsening of the mitral regurgitation (grade 3–4), with-
out vegetations.
On admission, he was febrile (38.2 °C). The physical exam-
ination found only the known mitral regurgitation murmur.
There was no sign of cardiac failure. Urine-analysis was normal.
Inflammatory parameters values were: ESR, 122 mm; C-reac-
tive protein (CRP), 122 mg/L. Three of six blood cultures
were positive for Aa. The rod was sensitive to: ampicillin,
third-generation cephalosporins, macrolides, tetracyclines,
aminoglycosides and fluoroquinolones (ofloxacin and
ciprofloxacin). Dental examination revealed the presence of an
infectious focus on tooth 47. Aa endocarditis was diagnosed.
Initial treatment was with amoxicillin and netilmicin. The
patient became afebrile on day 5 of treatment. On day 8,
intravenous treatment was rendered impossible due to insuf-
ficient peripheral venous access. Ofloxacin oral treatment at a
dosage of 200 mg three times daily was initiated. At this time,
the ESR was 120 mm and CRP, 47 mg/L. Ofloxacin MIC
against Aa was 0.03 mg/L by E-test. Fifteen days after the
beginning of ofloxacin treatment, peak serum concentration of
ofloxacin was 8.3 mg/L using high-performance liquid chro-
matography (Dr Jehl, Institut de Bacte´riologie, Strasbourg,
France).
The duration of ofloxacin treatment was 5 weeks. Apyrexia
persisted throughout the antibiotic treatment and inflammatory
parameters returned to normal values. A new echocardiograph
at the end of treatment confirmed the absence of vegetations
or further worsening of mitral regurgitation. One year later,
the patient remained free of clinical or biological signs of relapse.
In 1995, Babinchak reported a case of mitral prosthetic valve
Aa endocarditis successfully treated by ciprofloxacin (750 mg,
twice daily) [2]. The patient had no vegetations or cardiac
failure. The outcome was favorable. The minimum inhibitory
concentration (MIC) of ciprofloxacin against the rod was
0.019 mg/L. The serum level of ciprofloxacin at the steady state
was 4.1 mg/L 6 h after the intake of 750 mg, which cor-
responded to approximately 200-fold the MIC of ciprofloxacin.
We report a second case involving native mitral valve, in which
ofloxacin, given at high dosage, permitted achievement of
a peak serum level of more than 200-fold the MIC against
Aa.
In experimental models of endocarditis, the bactericidal
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activity of fluoroquinolones is correlated to the area under the
concentration curve (AUC) : MIC ratio; to the peak serum
level : minimal bactericidal concentration (MBC) ratio; and to
the time of exposure at concentrations greater than the MIC
[1]. Thus, there are strong arguments in favor of a potent
bactericidal activity of fluoroquinolones in Aa endocarditis [1]:
the very high serum concentration : MIC ratio observed in
these observations [2]; in our report, the relatively long half-
life of ofloxacin (about 8 h) [3]; a high concentration of fluoro-
quinolones in cardiac vegetations, as shown in experimental
endocarditis [1]. Otherwise, ciprofloxacin has been successfully
used to treat left-sided endocarditis due to Gram-negative
micro-organisms such as Salmonella enteritidis [4] and Yersinia
enterocolitica [5].
This new case report suggests the possibility of oral treatment
of endocarditis due to HACEK-organisms that are usually sen-
sitive to fluoroquinolones, such as Aa, Haemophilus sp., or
Eikenella. This drug regimen could be indicated as a follow-on
after 10–15 days duration of conventional intravenous treat-
ment if the patient presents no major valvular or cardiac dys-
function, and would allow an ambulatory follow-up after a
shortened initial hospitalization. Moreover, this drug regimen
may represent a valuable alternative treatment in case of b-
lactam intolerance.
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High frequency of asymptomatic shedding of herpes simplex virus
type 2 in African women
Clin Microbiol Infect 2000: 6: 56–57
Recently, the Rakai study tested the hypothesis that community-
level control of sexually transmitted disease (STD) would result in
lower incidence of HIV-1 infection in comparison with control
communities [1]. This randomized, controlled, single-masked,
community-based trial of intensive STD control, via home-based
mass antibiotic treatment, took place in Rakai District, Uganda.
Ten community clusters were randomly assigned to intervention
or control groups. All consenting residents aged 15–59 years were
enrolled, visited in the home every 10 months, interviewed,
asked to provide biological samples for assessment of HIV-1
infection and STD, and were provided with mass treatment
(azithromycin, ciprofloxacin, metronidazole in the intervention
group, vitamins/anthelmintic drug in the control group).
However, no effect of the STD intervention was observed on
the incidence of HIV-1 infection. In the Rakai population, a
substantial proportion of HIV-1 acquisition appears to occur
independently of treatable STD cofactors. Untreated genital
infections such as genital herpes might overwhelm any effects
associated with treatment of classic STD. In the Rakai study,
serological testing for herpes simplex virus type 2 (HSV-2)
revealed a high prevalence of 31% in men and 61% in women.
Furthermore, 43% of self-reported genital ulcers were for HSV-
2 by multiplex polymerase chain reaction (PCR). Asymptomatic
genital shedding of HSV-2 may be a cofactor of heterosexual
transmissionofHIV that was not investigated in the studypopulation
We have evaluated the frequency of asymptomatic genital
shedding of HSV-2 in women of childbearing-aged who were
attending the National Reference Center for Sexually Trans-
mitted Diseases of Bangui, the capital of the Central African
Republic. In this population, 80% of women were seropositive
for HSV-2 using a type-specific enzyme-linked immuno-
sorbent assay [2]. Cervicovaginal lavage samples were pro-
spectively obtained from 280 women without clinical evidence
of genital ulcers, of whom 78 (27.8%) were seropositive for
HIV-1. HSV-2 DNA sequences were detected in the acellular
part of cervicovaginal secretions by PCR followed by DNA
enzyme immunoassay hybridization. Seventy-nine (28.2%)
women were shedding HSV-2. The HSV-2 shedding was
nearly two-fold higher in HIV-infected women [41.0% (32 of
78)] in comparison with HIV-negative women [23.3% (47
of 202)] (P = 0.0001). These findings clearly demonstrate that
asymptomatic genital carriage of HSV-2 may be very common
in an African population that is highly seropositive for HSV-2.
Co-infection by HIV and HSV-2 increases the rate of
asymptomatic genital shedding of HSV-2. Asymptomatic rep-
lication of HSV-2 in the genital tract of HIV-infected women
may increase the genital replication of HIV [3,4], resulting in
